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DOI 10.1016/j.stem.2011.11.002The Court of Justice of the European
Union recently issued a judgment that
it is not acceptable under European law
to patent techniques for derivation of
other cell types from hESC lines. This
decision was a great disappointment for
many stem cell researchers and to the
patient groups who hope one day to be
treated with stem cell derivatives. As is
to be expected in law, there is a remorse-
less logic to this opinion given that the
role of the Court is to apply the rules
established by Parliament. However,
there is confusion in that the same
European Union that established these
rules also provides funding for research
with hESCs as do the parliaments of
several member states. In other words,
one arm of the EU is branding as immoral
a research activity that is being encour-
aged by another.
The basis of the case rests deep within
a series of treaties and agreementswhose
purpose is to create a commonmarket for
themembers of what is now the European
Union. The first of these was the Treaty of
Rome in 1957. Procedures for patenting
and limitations as to what may be the
subject of a patent have been described
in great detail since then.
Specifically, the judgment has its origin
in Directive 98/44 from the European
parliament and the Commission in 1998.
In Article 6 Paragraph 1 of that agreement
it is stated that:
Inventions shall be considered
unpatentable where their commer-
cial exploitation would be contrary
to ordre public or morality; how-
ever, exploitation shall not be
deemed to be so contrary merely
because it is prohibited by law or
regulation.
Paragraph 2
On the basis of paragraph 1, the
following, in particular, shall be
considered unpatentable:498 Cell Stem Cell 9, December 2, 2011 ª20(c) uses of human embryos
for industrial or commercial
purposes;.
The case was brought by Professor
Oliver Bru¨stle, who is Professor of Recon-
structive Neurobiology at the University of
Bonn and Co-Founder and Scientific
Director of LIFE & BRAIN GmbH. He and
his colleagues have a distinguished repu-
tation for their innovative research in
neurobiology. In December 1997 they
filed a patent describing a novel method
for the isolation of neural stem progenitor
cells from hESCs with the expectation
that they might form the basis of treat-
ments for neurodegenerative diseases
such as Parkinson’s disease. Greenpeace
were successful in obtaining a judgment
from the Federal Patent court of Germany
that aspects of the patent relating to
hESCs were invalid because it involved
use of hESCs. The Federal Court of
Justice decided to refer an appeal made
by Oliver Bru¨stle to the European Court
because the meaning of the term
‘‘embryo’’ had not been defined in
Directive 98/44. It was the final judgment
of this appeal that was published in
October. As summarized in the Press
Release, the Court found that, ‘‘A process
which involves removal of a stem cell
from a human embryo at the blastocyst
stage, entailing the destruction of that
embryo, cannot be patented.’’ In the
case of this patent it cannot ever be rein-
stated. Only a change in the directives
from the EU could lead to a different judg-
ment on a new application on a similar
invention.
This judgment contrasts starkly with
the fact that the EU in successive Frame-
work funding packages has supported
research with hESCs. Several member
countries including Finland, Greece, the
Netherlands, Sweden, and the UK allow
the production of hESC lines from surplus
IVF embryos. Indeed, in Germany the11 Elsevier Inc.2002 Stem Cell Act, revised in 2008,
allows the import of hESCs for specific,
approved research objectives. The hESC
lines must have been derived before
May 1, 2007 from surplus embryos pro-
duced by in vitro fertilization. Imposition
of this deadline was considered to ensure
that no hESC lines are produced specifi-
cally for the research in Germany.
Many scientists and others have ex-
pressed the view that this judgment
will delay the introduction of new thera-
pies to the disadvantage of patients. If
researchers are unable to patent their
inventions, they may find it more difficult
to obtain funding for research with
hESCs in Europe, in particular for the
translational phase of the development
of new therapies. This very expensive
phase of research is often funded by
companies who are persuaded that the
product has real potential. They may
invest either alone or in partnership with
government agencies, and they expect
to protect their investment by patenting
the new procedures. Of course it is
possible to seek patent protection in other
parts of the world, such as the USA and
Asia, but competing companies would
be able to use the method in Europe
with no fear of infringement.
Some commentators have argued
that the intention to apply for a patent
leads to greater secrecy in early phases
of the research, and that by contrast,
sequencing of the human genome was
accelerated by openness between labo-
ratories. However, in the case of a
genome, the novelty required to justify
a patent comes from development of
new uses of the sequence for a stated
purpose rather than a description of
the gene. It is hard to believe that
companies will invest heavily in new tech-
niques for differentiation of hESCs and
then release them for use by everyone.
Furthermore, secrecy is not a realistic
alternative. Detailed protocols for the
Cell Stem Cell
Lettersproduction of cells that are to be used
clinically will have to be provided when
organizations seek regulatory approval.
By contrast, patents provide transpar-
ency and thus facilitate competition and
progress.
The judgment refers only to ESCs, and
a great deal of research is being carried
out with other types of stem cells. A stated
objective of Greenpeace UK is to bring
pressure to increase research with alter-natives to hESCs. There is no doubt that
researchers do consider alternatives and
that great interest is placed upon iPSCs.
Patent applications made in the future
can encompass both sources of pluripo-
tent cells, but iPSCs are a relatively new
invention, so early applications such as
that made by Oliver Bru¨stle did not. It
would be wasteful and it would delay
treatment of patients if existing protocols
for use of hESC derivatives are not takenCell Stem Cell 9,to the clinic because the procedure
cannot be patented.
Finally, there is a real concern that
Europe will be perceived as reactionary
and resistant to progress in light of this
regulation and that as a result, companies
will choose to invest in other regions of the
world. It is certainly to be hoped that this is
not the case, because Europe has a fine
record of research with both embryonic
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DOI 10.1016/j.stem.2011.11.001The recentCourt of Justiceof the European
Union (2011) opinion in Bru¨stle v. Green-
peace caught the attention of the California
Institute for Regenerative Medicine (CIRM)
and many others as a result of its severe
restriction on the patentability of inventions
arising from embryonic-stem-cell-related
research. Strong criticism of the decision
immediately arose in some quarters, in-
cluding dire predictions that the ruling
marked the end of human embryonic stem
cell (hESC) research in Europe and, ulti-
mately, that Europewould not have access
to resulting therapies (Naik, 2011). At CIRM
we fund academic and commercial scien-
tists conducting stem cell research ranging
from basic science through to early clinical
work, and a significant proportion of our
funded projects involve hESCs. We appre-
ciate that patent protection can be an
important incentive for investment, and
that it also often promotes innovation as it
allows innovators time and a mechanism
to recoup their outlay (Rai et al., 2010).
Our view is that the impact of the recent
Court ruling on stem cell research and
regenerative medicine will be significant
but varied. In some instances, the ruling
may deter European hESC research, in
others such research may nonetheless
continue or even increase; in still others,
no impact may occur.In the area of basic or foundational
hESC research, for example, we would
not expect a significant impact from the
Court ruling provided scientists expect
that there will be continued funding of
such research by government and not-
for-profit entities. We would not expect
that a diminished ability to obtain patent
protection for basic research inventions
would materially decrease research fund-
ing from these sources. Government
funders tend to be less profit-driven than
commercial funders. Moreover, hESCs
presently remain the ‘‘gold standard’’ for
regenerative medicine research (Smith
et al., 2009; Fung and Kerridge, 2011).
We believe scientists conducting basic
research will be reluctant to focus exclu-
sively on adult stem cells or even induced
pluripotent stem cells (iPSCs) given the
unique advantages offered by hESCs.
With respect to translational hESC
research, the situation is more compli-
cated. At this stage of research and devel-
opment, profit-driven biotechnology and
pharmaceutical companies are more
actively involved. To the extent that the
lack of patent protection following the
Court ruling decreases the profit available
(e.g., because patented inventions cannot
be licensed and injunctions cannot be
obtained to protect hESC patented inven-tions), biotechnology and pharmaceutical
companies may be less motivated to
invest in European hESC research. That
effect may be even more dramatic for
startup companies. A strong patent port-
folio traditionally has been a prerequisite
for attracting venture capital in the life
sciences field. As reported by a U.S
Department of Commerce white paper,
‘‘In a large-scale survey conducted in
2008, 76% of startup managers reported
that VC investors consider patents impor-
tant to funding decisions.’’ (Rai et al.,
2010.)
On the other hand,wewould not predict
a complete dearth of European commer-
cial investment in the hESC sector in the
EU for several reasons. First, companies
can still protect some of their work as
traditional trade secrets. Second, as is
often said of biologics, ‘‘The product is
the process.’’ EU regulators will likely
require that any company wishing to
compete would have to incur the large
expense of preclinical and clinical trials
using their particular stem-cell-based
therapy (Tam, 2010). Third, to varying
degrees throughout Europe, the ‘‘Bolar
Exemption’’ (European Union, 2004)
limited patent protection for certain types
of research at this phase even before
the Court ruling. Finally, the effect of theDecember 2, 2011 ª2011 Elsevier Inc. 499
